Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carey Anders

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Oncology (Williston Park, N.Y.)|November 5, 2008
Understanding and treating triple-negative breast cancerCarey Anders, Lisa A Carey
Current Treatment Options in Oncology|March 20, 2021
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast CancerJames Isaacs, Carey Anders, Heather McArthur, et al.
Neuro-Oncology|March 8, 2023
Progress for patients with melanoma brain metastasesPaul W Sperduto, April K S Salama, Carey Anders
Clinical Breast Cancer|November 30, 2019
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSarah Sammons, Mythili Shastry, Susan Dent, et al.
Breast Cancer Research and Treatment|September 10, 2025
Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancerSara Nezirevic, Carey Anders, Susan Dent, et al.
Clinical Breast Cancer|September 6, 2016
Coordination of Care for Breast Reconstruction Patients: A Provider SurveyJennifer L Milucky, Allison M Deal, Carey Anders, et al.
Cancer Control : Journal of the Moffitt Cancer Center|April 19, 2025
Real-World Clinical Outcomes in Patients With HER2+ Metastatic Breast Cancer Receiving Tucatinib-Based Therapy After 2 or More Prior Metastatic HER2-Directed RegimensCarey Anders, Edward Neuberger, Karen Bartley, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2024
"Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized toolsEmilie Le Rhun, Michael Weller, Carey Anders, et al.
Breast Cancer Research and Treatment|June 15, 2011
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapseJ Chuck Harrell, Aleix Prat, Joel S Parker, et al.
International Journal of Clinical Oncology|August 6, 2025
Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databasesCarey Anders, Edward Neuberger, Naomi R M Schwartz, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Oncology (Williston Park, N.Y.)|November 5, 2008
Understanding and treating triple-negative breast cancerCarey Anders, Lisa A Carey
Current Treatment Options in Oncology|March 20, 2021
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast CancerJames Isaacs, Carey Anders, Heather McArthur, et al.
Neuro-Oncology|March 8, 2023
Progress for patients with melanoma brain metastasesPaul W Sperduto, April K S Salama, Carey Anders
Clinical Breast Cancer|November 30, 2019
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSarah Sammons, Mythili Shastry, Susan Dent, et al.
Breast Cancer Research and Treatment|September 10, 2025
Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancerSara Nezirevic, Carey Anders, Susan Dent, et al.
Clinical Breast Cancer|September 6, 2016
Coordination of Care for Breast Reconstruction Patients: A Provider SurveyJennifer L Milucky, Allison M Deal, Carey Anders, et al.
Cancer Control : Journal of the Moffitt Cancer Center|April 19, 2025
Real-World Clinical Outcomes in Patients With HER2+ Metastatic Breast Cancer Receiving Tucatinib-Based Therapy After 2 or More Prior Metastatic HER2-Directed RegimensCarey Anders, Edward Neuberger, Karen Bartley, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2024
"Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized toolsEmilie Le Rhun, Michael Weller, Carey Anders, et al.
Breast Cancer Research and Treatment|June 15, 2011
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapseJ Chuck Harrell, Aleix Prat, Joel S Parker, et al.
International Journal of Clinical Oncology|August 6, 2025
Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databasesCarey Anders, Edward Neuberger, Naomi R M Schwartz, et al.
Pageof 4